SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-013648 to Ainos, Inc. (AIMD, AIMDW) (CIK 0001014763) (AIMD)

Ainos, Inc. (AIMD, AIMDW) (CIK 0001014763)
Date: Dec. 14, 2023 · CIK: 0001014763 · Accession: 0000000000-23-013648

AI Filing Summary & Sentiment

File numbers found in text: 333-275971

Date
December 14, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Ainos, Inc. (AIMD, AIMDW) (CIK 0001014763)

Letter

United States securities and exchange commission logo December 14, 2023 Chun-Hsien Tsai Chief Executive Officer Ainos, Inc. 8880 Rio San Diego Drive, Ste. 800 San Diego, CA 92108 Re:Ainos, Inc. Registration Statement on Form S-1 Filed December 8, 2023 File No. 333-275971 Dear Chun-Hsien Tsai : This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Carol B. Stubblefield

Show Raw Text
United States securities and exchange commission logo
December 14, 2023
Chun-Hsien Tsai
Chief Executive Officer
Ainos, Inc.
8880 Rio San Diego Drive, Ste. 800
San Diego, CA 92108
Re:Ainos, Inc.
Registration Statement on Form S-1
Filed December 8, 2023
File No. 333-275971
Dear Chun-Hsien Tsai :
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Carol B. Stubblefield